Browsing Tag
Mavorixafor
2 posts
Will mavorixafor’s EU path mirror its U.S. regulatory breakthrough in WHIM syndrome?
X4 Pharmaceuticals (NASDAQ: XFOR) wins EMA backing for mavorixafor. Explore what EU approval could mean for revenue, risk, and rare disease strategy.
X4 Pharmaceuticals (NASDAQ: XFOR) gets FDA fast track for mavorixafor in chronic neutropenia
X4 Pharmaceuticals (XFOR) secures FDA Fast Track for mavorixafor in chronic neutropenia, targeting trial completion in 2025 and results in 2026.